Memantine Synthon

Memantine Hydrochloride, the active ingredient in Memantine Synthon, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients. GNH USA supplies Memantine Synthon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine Hydrochloride is an NMDA receptor antagonist used in the management of Alzheimer’s disease. - Alzheimer’s disease (moderate to severe): helps improve cognition, functional abilities and daily living activities.

Memantine Hydrochloride may be associated with several adverse reactions.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate cranial pain. - Constipation: reduced bowel movements. - Confusion: transient disorientation or difficulty concentrating. - Somnolence: increased sleepiness or fatigue.

Serious or Rare Side Effects: - Seizures: occurrence of convulsive episodes. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: rare severe skin reaction. - Hepatic dysfunction: abnormal liver enzyme elevations. - Cardiac arrhythmias: irregular heart rhythms.

When prescribing Memantine Hydrochloride, clinicians should consider several safety aspects. - Renal impairment: adjust dose or monitor renal function. - History of seizures: monitor for increased seizure activity. - Cardiovascular disease: assess blood pressure and heart rate. - Use in elderly: watch for confusion or falls. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Memantine Hydrochloride can interact with other medications, requiring attention to potential additive effects.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase CNS depression. - Ketamine: additive NMDA blockade can intensify neurological effects. - Other NMDA antagonists: concurrent use may lead to excessive inhibition.

Moderate Interactions (Monitor Closely): - Antihypertensives: may enhance hypotensive response. - Diuretics: risk of dehydration and electrolyte imbalance. - Anticholinergics: may worsen cognitive impairment.